QUEBEC CITY–(BUSINESS WIRE)–Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today the nomination of Dr Andre P. Boulet, PhD, as representative of Canada within the American Botanical Drug Association (ABDA).
“I am honored to join the American Botanical Drug Association. Until 2018, the US-FDA has received over 800 botanical investigational new drug applications (IND)1. It can be anticipated that, in coming years, more Botanical Drugs will be approved in the USA with collateral benefits for Canadians patients. I look forward to contributing to ABDA and to the Botanical Drug field,” said Dr Boulet, President and Chief Executive Officer of Devonian.
“Dr. Boulet is a pioneer in botanical drug field. His vision about the botanical drug industry goes back to year 2007 when the US FDA botanical drug guidance was rarely known by pharmaceutical professionals. Over the years, Dr. Boulet has put his vision to action and developed a leading botanical drug corporation in Canada. We (ABDA) recognize his contribution and his leadership and we are delighted to have him join us to develop this emerging industry,” said Dr Roger Luo, PhD, Chairman of the American Botanical Drug Association.
About the American Botanical Drug Association (ABDA).
American Botanical Drug Association is an industry trade organization for worldwide herbal manufactures and companies, with a mission to:
- Increase public awareness of botanical drugs
- Increase options in the healthcare system
- Facilitate healthcare policy formation
- Serve as a platform for dialogues and collaboration among government agencies, private enteritis, and academics, by means of conferences and meetings
- Promote collaboration between the pharmaceutical industry and the botanical and herbal industry
- Establish international standards for botanical drugs and its medical usage
ABDA collaborates with research institutes and companies to develop safe and efficacious herbal medicine to US prescription botanical drugs through US FDA botanical Drug Development Guidance for Industry. ABDA has built significant influence in the field of botanical drug industry not only in the US, but also in areas with rich botanical resources like Asia. ABDA is expanding to South America, Africa and Europe.
For more information, visit www.BotanicalDrug.org
Devonian Health Group Inc. is a late stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Acquired in 2018, Altius Healthcare Inc., its commercialization partner, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSXV Exchange (TSXv:GSD).
For more information, visit www.groupedevonian.com
- Wu C., Lee S-L, Taylo, C. rt al. Scientific and Regulatory Approach to Botanical Drug development : A U.S. FDA Perspective, J. Nat. Prod. 2020, 83, 552-562
Forward Looking Statements
This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.